159 related articles for article (PubMed ID: 37055606)
1. Coexistence of a novel SETD2-ALK, EML4-ALK double-fusion in an advanced lung adenocarcinoma patient after alectinib resistant and response to immunotherapy combined with chemotherapy: a case report.
Zhu L; Qin J
Discov Oncol; 2023 Apr; 14(1):44. PubMed ID: 37055606
[TBL] [Abstract][Full Text] [Related]
2. Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.
Liang Q; Xu H; Liu Y; Zhang W; Sun C; Hu M; Zhu Y; Tan S; Xu X; Wang S; Liu L
Lung Cancer; 2021 Dec; 162():86-89. PubMed ID: 34763158
[TBL] [Abstract][Full Text] [Related]
3. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT
J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase (
Li J; Huang K; Ji H; Qian J; Lu H; Zhang Y; Russo A; Romero A; Urbanska EM; Tabbò F; Zhao X; Chu T
Transl Lung Cancer Res; 2023 Dec; 12(12):2505-2519. PubMed ID: 38205204
[TBL] [Abstract][Full Text] [Related]
5. Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.
Guo W; Liang J; Zhang D; Huang X; Lv Y
Medicine (Baltimore); 2022 Oct; 101(40):e30913. PubMed ID: 36221356
[TBL] [Abstract][Full Text] [Related]
6. Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC.
Bokhari AA; Lai WY; Le AT; Gabre JL; Chuang TP; Fransson S; Bergman B; Djos A; Chen N; Martinsson T; Van den Eynden J; Doebele RC; Palmer RH; Hallberg B; Umapathy G
Lung Cancer; 2022 Sep; 171():103-114. PubMed ID: 35933914
[TBL] [Abstract][Full Text] [Related]
7. A case report of exceptional clinical response to chemoradiotherapy and tyrosine kinase inhibitors in a patient with EML4-ALK fusion variant 1 non-small cell lung cancer.
Xu X; Liu D; Wen J; Chen J; Fan M
Transl Lung Cancer Res; 2020 Dec; 9(6):2500-2507. PubMed ID: 33489810
[TBL] [Abstract][Full Text] [Related]
8. Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.
Woo CG; Seo S; Kim SW; Jang SJ; Park KS; Song JY; Lee B; Richards MW; Bayliss R; Lee DH; Choi J
Ann Oncol; 2017 Apr; 28(4):791-797. PubMed ID: 28039177
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
10. Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance.
Liu D; Xu X; Wen J; Zhang C; Fan M
Lung Cancer; 2021 Oct; 160():32-35. PubMed ID: 34391065
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion.
Yin Q; Guo T; Zhou Y; Sun L; Meng M; Ma L; Wang X
Thorac Cancer; 2022 Feb; 13(4):637-642. PubMed ID: 34964276
[TBL] [Abstract][Full Text] [Related]
12. Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant.
Song P; Zhang J; Shang C; Zhang L
Thorac Cancer; 2018 Oct; 9(10):1327-1332. PubMed ID: 30133144
[TBL] [Abstract][Full Text] [Related]
13. Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).
Isozaki H; Hotta K; Ichihara E; Takigawa N; Ohashi K; Kubo T; Ninomiya T; Ninomiya K; Oda N; Yoshioka H; Ichikawa H; Inoue M; Takata I; Shibayama T; Kuyama S; Sugimoto K; Harada D; Harita S; Sendo T; Tanimoto M; Kiura K
Clin Lung Cancer; 2016 Nov; 17(6):602-605. PubMed ID: 27405684
[TBL] [Abstract][Full Text] [Related]
14. A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4 years by switching to ceritinib.
Matsumura Y; Inomata S; Yamaguchi H; Mine H; Takagi H; Watanabe M; Ozaki Y; Yamaura T; Fukuhara M; Muto S; Okabe N; Hasegawa T; Shio Y; Suzuki H
Thorac Cancer; 2021 Aug; 12(15):2225-2228. PubMed ID: 34159737
[TBL] [Abstract][Full Text] [Related]
15. Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer.
Wolf J; Helland Å; Oh IJ; Migliorino MR; Dziadziuszko R; Wrona A; de Castro J; Mazieres J; Griesinger F; Chlistalla M; Cardona A; Ruf T; Trunzer K; Smoljanovic V; Novello S
ESMO Open; 2022 Feb; 7(1):100333. PubMed ID: 35042152
[TBL] [Abstract][Full Text] [Related]
16. Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy.
Zhai X; Wu Q; Pu D; Yin L; Wang W; Zhu D; Xu F
Front Oncol; 2021; 11():782682. PubMed ID: 35070986
[TBL] [Abstract][Full Text] [Related]
17. Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
Peters S; Zimmermann S
Curr Treat Options Oncol; 2018 May; 19(7):37. PubMed ID: 29808239
[TBL] [Abstract][Full Text] [Related]
18. Combinatorial therapy is a safe and durable treatment option in
Jang C; Sabari J
Transl Lung Cancer Res; 2023 Dec; 12(12):2558-2564. PubMed ID: 38205199
[TBL] [Abstract][Full Text] [Related]
19. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
[TBL] [Abstract][Full Text] [Related]
20. Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines.
Chen Y; Ma G; Su C; Wu P; Wang H; Song X; Yu Q; Zeng A; Zhou S
Anticancer Drugs; 2018 Nov; 29(10):935-943. PubMed ID: 30074936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]